Primary Care Dermatology Society Website
NICE NG169: COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response
NICE NG198: Acne vulgaris: management
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
CD&D Patient Decision Aids Resource available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/
NHS England Guidance on “Conditions for which over the counter items should not routinely be prescribed” available at: https://www.england.nhs.uk/medicines/conditions-for-which-over-the-counter-items-should-not-routinely-be-prescribed/
Prescribing of medicines available to purchase over the counter for self-care
Potassium Iodide 60mg and 300mg capsules
Approved for neutrophilic dermatoses (Sweet syndrome and pyoderma gangrenosum) and panniculitis (including erythema nodosum and nodular vasculitis) Dermatology only
Unlicensed product
Poor evidence base. More cost effective preparations available
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
See local guideline on emollient prescribing for dry skin conditions: Area Prescribing Committee website or CDDFT Intranet
MHRA Drug Safety Update (April 2016): Paraffin-based skin emollients on dressings or clothing: fire risk
MHRA Drug Safety Update (Dec 2018): Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients
MHRA Drug Safety Update (Aug 2020): Emollients and risk of severe and fatal burns: new resources available
Plain Emollients
First choice
Second choice
Third line
Prescribing usually reserved for dermatology services.
As of September 2018 Emollient Bath Additives are no longer in included in the formulary on then basis of BATHE trial no evidence to support routine use of bath emollients. Also due to risk of slipping due to emollient application in bath.
Dermatology confirmed that they do not routinely prescribe these products.
Plain Emollients
First choice
Second choice
Third line
Prescribing usually reserved for dermatology services.
Aveeno, E45, Diprobase and Epaderm products do not feature on the County Durham and Tees Valley APC formulary therefore use should be restricted. If patients are currently prescribed one of these emollients then they should be substituted to another emollient as described below:
1. Patients prescribed Epaderm Ointment should be switched to Hydromol Ointment or Zeroderm
Ointment
2. Patients prescribed Diprobase Cream should be changed to Zerobase Cream as ingredients are similar (there is a higher percentage of liquid paraffin to aid smoothing into sensitive skin)
3. Patients prescribed E45 Cream should be prescribed a suitable emollient from the formulary first line choices listed above, since there is no direct equivalent product
4. Patients prescribed Aveeno should be switched to Zeroveen
5. In addition to this Aqueous Cream is no longer recommended as a “leave on” emollient (Aqueous cream: may cause skin irritation Drug Safety Update)
Any patients using Aqueous Cream as an emollient should be switched to an alternative product. The first choice for this would be Hydromol Ointment as this is also suitable as a soap substitute.
BE AWARE OF THE POTENTIAL FIRE HAZARD WITH PARAFFIN BASE SKIN PRODUCTS
NHS England (June 2019) advises that that prescribers in primary care should not initiate bath and shower preparations for any new patient. Prescribers should be supported to deprescribe bath and shower preparations and substitute with “leave-on” emollients, which may also be used as a soap substitute.
A multicentre pragmatic parallel group RCT looking at emollient bath additives for the treatment of childhood eczema (BATHE) showed that there was no evidence of clinical benefit for including emollient bath additives in the standard management of childhood eczema.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
OintmentOTC
Yellow soft paraffin 30%, emulsifying wax 30% & liquid paraffin 40%.
Also used as soap substitute.
CreamOTC
10% liquid paraffin, 10% isopropyl myristate & 0.1% benzalkonium chloride & 0.1% chlorhexidine chloride
50g, 200g and 500g creamOTC
2nd line emollient for use in teenage girls as it contains a rose fragrance which may aid compliance.
OintmentOTC containing titanium oxide 20%, titanium peroxide 5% and titanium salicylate 3% in a basis containing dimeticone, paraffins and benzoin compound tincture
NICE TA81: Frequency of application of topical corticosteroids for atopic eczema
MHRA Drug Safety Update (Aug 2017): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
MHRA Drug Safety Update (Sep 2021): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions
NICE advise that use of topical antibiotics in children with atopic eczema, including those combined with topical corticosteroids, should be reserved for cases of clinical infection in localised areas and limited to a maximum of two weeks treatment. They should not be put on repeat prescription.
Ointment (clobetasol propionate 0.05%, neomycin sulphate 0.5%, nystatin 100,000 units/g) u
2nd line use only.
100g
Indication: control of eczema that gets infected recurrently.
Unlicensed
Cream, Ointment 30g
1st line use
0.1% cream, ointment, lotion & scalp application
Cream 30g
15g available Over the Counter.
Cream 30g (15g available Over the Counter).
Ointment 30g
Cream (chlorhexidine HCl 1%, nystatin 100,000 units/g & hydrocortisone 0.5%)
2nd line use only.
10mg and 30mg capsules
Approved for use as a treatment option for adults with severe chronic hand eczema that have not responded to potent topical corticosteroids in accordance with NICE guidance.
MHRA Drug Safety Update (Jun 2019): Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
MHRA Drug Safety Update (July 2021): Oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic
Scalp Ointment
Coal tar lotion 1% - see Exorex
Coal tar strong solution 1%, 2.5% & 5% in emulsifying
ointment RVI u
Lotion containing prepared coal tar 1% in an emollient basis. Excipients include hydroxybenzoates (parabens) and polysorbate 80.
Pomade containing 6% coal tar solution and salicylic acid 2% in an emulsifying ointment baseu
0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6% & 8%u
Unlicensed
0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6%, 8% & 16% in emulsifying baseu
Unlicensed
Dithranol 1% and salicylic acid 2% in emulsifying ointment 100g
Dithranol 2% and salicylic acid 2% in emulsifying ointment 100g
Dithranol 4% and salicylic acid 2% in emulsifying ointment 100g
Dithranol 8% and salicylic acid 2% in emulsifying ointment 100g
Dithranol 16% and salicylic acid 2% in emulsifying ointment 100g
Indication: Chronic plaque psoriasis predominantly used as short contact treatment for
outpatients coming in for daily treatments
Unlicensed
50 micrograms/g (0.005%) cream & ointment
50 micrograms/ml (0.005%) scalp application
2%, 5%, 10% & 20% in emulsifying ointment
Salicyclic acid 1% in aqueous cream 100g
Salicyclic acid 2% in aqueous cream 100g
All unlicensed
Capsules - 10mg, 25mgu
Consultant only
MHRA Drug Safety Update (Jun 2019): Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
MHRA Drug Safety Update (July 2021): Oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic
30mg & 120mg tablets (Skilarence®)
Dimethyl fumarate for moderate to severe chronic plaque psoriasis
Approved for use in accordance with the following NICE TAs:
40mg injection (prefilled syringe)
Approved for use in accordance with the following NICE TAs:
Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of preferred biosimilar brand.
10mg, 20mg and 30mg film coated tabletes
Approved for use in accordance with the following NICE TAs:
MHRA Drug Safety Update (Jan 2017): Apremilast (Otezla ): risk of suicidal thoughts and behaviour
2mg and 4mg tablets
Approved for use in accordance with the following NICE TAs:
MHRA Drug Safety Update (Mar 2020): Baricitinib (Olumiant▼): risk of venous thromboembolism
MHRA Drug Safety Update (Aug 2020): Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors
160 mg solution for injection in pre-filled pen
Approved for use in accordance with the following NICE TAs:
210mg solution in pre-filled syringe
Approved for use in accordance with the following NICE TAs:
200mg/ml soln in pre-filled pen or syringe
Approved for use in accordance with the following NICE TAs:
CD&D APC Shared Care Guideline available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/transfer-of-prescribing-policies-shared-care-guidelines/
Not approved in accordance with the following NICE TAs:
Commissioner: NHS England
300mg/2ml soln for inj in pre-filled syringe
Approved for use in accordance with the following NICE TAs:
25mg injection (Enbrel® & Benapali®)
NTAG April 2016: The Northern (NHS) Treatment Advisory Group recommends the use of etanercept biosimilar Benepali® as an option for use in adults where the originator product (Enbrel®) would normally be prescribed.
Approved for use in accordance with the following NICE TAs:
Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of preferred biosimilar brand.
150mg pre-filled syringe
Approved for use in accordance with the following NICE TAs:
100mg injection (Remicade®, Inflectra® & Remsima®)
120 mg solution for injection in pre-filled syringe or pre-filled pen for subcutaneous injection (Remsima®)
Approved for use in accordance with the following NICE TAs:
NTAG September 2015: The Northern (NHS) Treatment Advisory Group recommends the use of infliximab biosimilars as an option where the originator product (Remicade®) would normally be prescribed.
NTAG June 2020: The Northern (NHS) Treatment Advisory Group recommends Remsima SC® be available as additional treatment option during the COVID-19 pandemic for both licensed and off-label uses as part individual hospital Trust management strategies to reduce hospital day case admissions, and keep immunosuppressed people out of hospital during the COVID-19 pandemic. Remsima SC® could be considered as an option where the patient would otherwise get the intravenous Remsima® formulation of Infliximab. This recommendation is subject to any off-label use of Remsima SC® being considered and approved via individual hospital trust governance processes (including clinical governance) for the use of unlicensed/off-label drugs. It was also agreed that this recommendation would be reviewed after 12 months. In June 2021 NTAG reviewed this recommendation after 12 months as agreed. NTAG agreed at this time to make no changes to the recommendation due to the ongoing COVID-19 pandemic and review the position again in a further six months time.
Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of preferred biosimilar brand.
80mg solution for injection in prefilled pen.
Approved for use in accordance with the following NICE TAs:
Shared Care documents available
See local guideline on emollient Low-dose Methotrexate for Eczema – A Guideline for Paediatric Prescribing – found here
CD&D APC Shared Care Guideline available at: http://medicines.necsu.nhs.uk/guidelines/durham-darlington/transfer-of-prescribing-policies-shared-care-guidelines/
Cream - 1%
AMBER SPECIALIST INITIATION
Prescribed in accordance with NICE TA82
75mg soln for inj in pre-filled pen
Approved for use in accordance with the following NICE TAs:
150microgram pre-filled pen & syringe
Approved for use in accordance with the following NICE TAs:
100mg soln for injection in pre-filled syringe
Approved for use in accordance with the following NICE TAs:
45mg vial
Approved for use in accordance with the following NICE TAs:
MHRA Drug Safety Update (Jan 2015): Ustekinumab (Stelara): risk of exfoliative dermatitis
Acne is a common skin condition that affects most people at some point. Although acne can’t be cured, it can be controlled with treatment. Several creams, lotions and gels for treating acne are available at pharmacies. Treatments can take up to three months to work. Patients should be encouraged to manage mild acne with long term use of over the counter products.
1% topical solution (alcohol – water basis)
1% lotion (aqueous)
Antibacterial agent not for continual use
Topical solution containing erythromycin 4% zinc acetate 1.2% (when reconstituted)
Duac Once Daily 10 mg/g + 30 mg/g Gel - 1 g of gel contains: 10 mg (1 % w/w) clindamycin as clindamycin phosphate and 30 mg (3 % w/w) anhydrous benzoyl peroxide as hydrous benzoyl peroxide
Duac Once Daily 10 mg/g + 50 mg/g Gel - 1 g of gel contains: 10 mg clindamycin as clindamycin phosphate and 50 mg anhydrous benzoyl peroxide as hydrous benzoyl peroxide
See section 5.1 for systemic antibiotics
Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms
Generic co-cyprindiol is much cheaper than Dianette®
For use in women only
Capsules - 5mg, 20mg
Isotretinoin is a toxic drug that must only be prescribed by or under the supervision of a consultant dermatologist.
Supplied in accordance with companies pregnancy prevention programme. Women of child bearing age will only be supplied 1 month. See BNF for further details
MHRA Drug Safety Update (Dec 2014): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders
MHRA Drug Safety Update (Oct 2017): Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido
MHRA Drug Safety Update (Jun 2019): Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
MHRA Drug Safety Update (Aug 2020): Isotretinoin (Roaccutane▼): reminder of important risks and precautions
MHRA Drug Safety Update (July 2021): Oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic
Unlicensed indication when used for female patients intolerant or not responding to isotretinoin.
Do not take this medication if you are pregnant or planning to become pregnant as it can affect the normal development of your unborn child.
Women taking spironolactone should use effective contraception to prevent pregnancy.
0.33% gel
Not approved: Brimonidine tartrate for facial erythema in rosacea
MHRA Drug Safety Update (Nov 2016): Brimonidine gel (Mirvaso): risk of exacerbation of rosacea
MHRA Drug Safety Update (June 2017): Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin
Not approved for use in County Durham and Tees Valley to treat facial erythema due to safety concerns
regarding exacerbation of rosacea and cardiovascular safety if applied to damaged skin
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
75% & 95% applicators – 6 inch & 95% pencils (Caustic pencils). 0.5% solution also available see section 13.11.6
Paint (salicylic acid 16.7% & lactic acid 16.7% in flexible collodion)OTC
Various strength preparations in Emulsifying ointmentu – see section 13.5.2
0.15% cream (Warticon)
To be initiated with specialist advice
5% cream 12 sachet pack
- 2nd line specialist use for treatment of ano-genital warts (mainly in genitourinary medicine [GUM] clinics)
10%, 75% & 90% solutions
90% w/v 10 ml - Used to destroy facial xanthelasmata; highly irritant
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Cream (UVB – SPF 30) - mexenone 2%, ethylhexyl pmethoxycinnamate 7.5%, Butylmethoxydibenzoylmethane 4% & titanium dioxide 6.5%
Sunscreens are limited to patients that are having treatment that may render them susceptible to sunlight only as per ACBS guidelines.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Lotion (UVA and UVB – SPF 50+ protection) – containing octinoxate 7.5%, oxybenzone 3%, titanium dioxide 3.5% - 125ml pack
Sunscreens are limited to patients that are having treatment that may render them susceptible to sunlight only as per ACBS guidelines.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
5% cream
For the treatment of superficial malignant and premalignant skin lesions
For the management of actinic keratosis.
5 mg of fluorouracil and 100 mg of salicylic acid (SPC) (0.5% 5-FU and 10% salicylic acid)
For the management of actinic keratosis.
Klisyri(R) 10 mg/g ointment
Indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.
Note: No clinical data on treatment for more than 1 treatment course of 5 consecutive days are available If recurrence occurs, or new lesions develop within the treatment area, other treatment options should be considered.
To be used as per Primary Care Dermatology Society Guidelines for actinic keratosis when these are updated to include Tirbanibulin.
Products from the Dermacolor® Camouflage Crème and Veil cover cream ranges are included in this Formulary. They are classified as borderline substances and can be prescribed on FP10 prescription forms (marked ACBS) for postoperative scars and other deformities and as an adjunctive therapy in the relief of emotional disturbances due to disfiguring skin disease, such as vitiligo.
Minoxidil 5% scalp foam
Not a cost effective use of NHS resources. All other forms of topical minoxidil are black-listed in the Drug Tariff.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Tablets containing cyproterone acetate 2mg &
ethinylestradiol 35 micrograms
Generic co-cyprindiol is much cheaper than Dianette
11.5% cream
Approved for use with laser therapy only.
No evidence of efficacy in comparison to existing treatments and it is substantially more expensive. It needs to be used indefinitely but the long-term benefits and safety have not been established (past 24 weeks). To be used only in line with laser therapy.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Reserve topical antibiotics for very localised lesions to reduce risk of resistance
Systemic treatments are more effective. Nail lacquers and solutions are expensive. Amorolfine nail lacquer (pack size 3ml s) is available OTC for mild cases and for treatment of a maximum of two nails
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Poor evidence base
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
Poor evidence base
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
MHRA Drug Safety Update (March 2018): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition, eg, cigarettes
4% lotion (50ml) (Hedrin®)OTC
Live head lice can be treated by wet combing; chemical treatment is only recommended in exceptional circumstances and in these cases over the counter medicines can be purchased from a pharmacy. If appropriate everyone in the household needs to be treated at the same time – even if they don’t have symptoms. Further information on how to treat head lice without medication can be found on NHS Choices.
0.5% lotion (aqueous), 0.5% lotion (alcoholic)OTC
Live head lice can be treated by wet combing; chemical treatment is only recommended in exceptional circumstances and in these cases over the counter medicines can be purchased from a pharmacy. If appropriate everyone in the household needs to be treated
at the same time – even if they don’t have symptoms. Further information on how to treat head lice without medication can be found on NHS Choices.
5% skin cream; 1% cream rinseOTC
Live head lice can be treated by wet combing; chemical treatment is only recommended in exceptional circumstances and in these cases over the counter medicines can be purchased from a pharmacy. If appropriate everyone in the household needs to be treated at the same time – even if they don’t have symptoms. Further information on how to treat head lice without medication can be found on NHS Choices.
OTC
Live head lice can be treated by wet combing; chemical treatment is only recommended in exceptional circumstances and in these cases over the counter medicines can be purchased from a pharmacy. If appropriate everyone in the household needs to be treated at the same time – even if they don’t have symptoms. Further information on how to treat head lice without medication can be found on NHS Choices.
Oily emulsion containing 0.1% Proflavine hemisulphate –
for limited use in hospitals
Not a cost effective use of NHS resources Cochrane Review 2014: Interventions
for treating painful nipples among breastfeeding women.
The County Durham and Tees Valley APC Do Not Prescribe List and Grey List can be accessed online at: https://medicines.necsu.nhs.uk/download/tees-prescribing-grey-list/
2ml, 4ml & 10ml kit
Also approved for use in the treatment of mesh fixation in hernia repair.
4.8 & 9.5 sq cm Haemostatic (collagen sponge coated with
fibrinogen and thrombin) for use in liver and renal surgery
Containing 70% isopropyl alcohol or methylated spirit (e.g. Clini-wipes®, Alcowipes®)
Sterile solution – bottles, 25ml & 100ml sachets (Normasol®) & 45ml plastic ampoules/pods (Miniversol®)
1% chlorhexidine acetate dusting powder
Chlorhexidine Gluconate 0.02% & 0.05% solutions, 25ml & 100ml sachets
0.5% solution in 70% methylated spirit (pink, colourless &
red staining),
2.5% in 70% methylated spirit wipes
0.5% hand rub (contains 70% isopropyl alcohol + emollients)
4% surgical scrub
2% in 70% isopropyl alcohol wipes (Sanicloth® & Clinell®),
skin swabs & skin cleanser
3ml & 10.5ml applicators (Chloraprep®)
Obstetric cream
MHRA Medical Device Alert (November 2012) re: chlorhexidine and risk of anaphylaxis
MHRA Drug Safety Update (November 2014) reminder of the risk of chemical burns in premature infants
Paint containing brilliant green and crystal violetu – for limited use in some operating theatres only
0.5% paintu - for limited use in some operating theatres / critical care areas only
Sterile larvae (maggots) used for the management of sloughy wounds.
CDDFT Intranet link Policy for the use of sterile maggots in wound management within in-patient settings
Aluminium chloride hexahydrate 20% solution in an alcoholic basis (Driclor®, Anhydrol forte®)OTC
Hyperhidrosis is a common condition in which a person sweats excessively. First line treatment involves simple lifestyle changes. It can also be treated with over the counter high strength antiperspirants. An antiperspirant containing aluminium chloride is usually the first line of treatment and is sold in most pharmacies.
Most prescribing uses licensed medicines whose safety and efficacy are assured. For many common dermatological diseases including psoriasis and eczema, the range of licensed medicines is limited. As a result, Dermatology prescribing may rely significantly on unlicensed creams and ointments (known as ‘Specials’) containing tars, dithranol, salicylic acid, steroids and other active constituents in a range of concentrations and bases. This is of particular concern in primary care where lack of effective price controls and a mechanism to ensure independent scrutiny of product quality has increased costs and concern about standards. To address these concerns, and help optimise quality of care, adherence to the revised British Association of Dermatologists (BAD) list of preferred Specials (2018) is encouraged.
Specials Recommended by the British Association of Dermatologists for Skin Disease (2018)
Products included in 2018 BAD Specials List
|
Category |
Product |
|
Formulary RAG status in County Durham & Tees Valley |
|
EMOLLIENTS AND BARRIERS |
Propylene glycol 20% w/w in aqueous cream |
100g |
Non-formulary |
|
Propylene glycol 40% w/w in aqueous cream |
100g |
Non-formulary |
|
|
Propylene glycol 50% w/w in water |
100ml |
Non-formulary |
|
|
STEROID COMBINATIONS |
Salicylic acid 5% w/w / propylene glycol 47.5% w/w in clobetasol propionate 0.05% (Dermovate®) cream |
100 g |
AMBER SI |
|
Propylene glycol 40% w/w in clobetasol propionate 0.05% (Dermovate®) Cream |
100g |
Non-formulary |
|
|
Coal tar solution BP 5% w/w in betamethasone valerate 0.025% w/w ointment |
100g |
AMBER SI |
|
|
Coal tar solution BP 3.3% w/w and propylene glycol 20% w/w in fluocinolone acetonide 0.025% (Synalar®) gel |
100g |
AMBER SI |
|
|
Beclomethasone dipropionate 0.0025% w/w in WSP BP ointment (formerly known as Propaderm® 1 in 10) |
100g |
AMBER SI |
|
|
TARS |
Coal tar scalp application (‘coal tar pomade’; coal tar solution BP 6% w/w / salicylic acid 2% w/w in emulsifying ointment) |
100g |
RED |
|
Coal tar BP 2% w/w in YSP |
100g |
RED |
|
|
Coal tar BP 5% w/w in YSP |
100g |
RED |
|
|
Coal tar BP 10% w/w in YSP |
100g |
RED |
|
|
Coal tar solution BP 6% w/w and salicylic acid 6% w/w in Ung. Merck |
100g |
AMBER SI |
|
|
ICHTHAMMOL |
Ichthammol 1% w/w and zinc oxide 15% w/w in YSP |
200g |
Non-formulary |
|
DITHRANOL PREPARATIONS |
Dithranol in Lassar's paste 0.1% w/w |
100g |
RED |
|
Dithranol in Lassar's paste 0.5% w/w |
100g |
RED |
|
|
Dithranol in Lassar's paste 1% w/w |
100g |
RED |
|
|
Dithranol in Lassar's paste 2% w/w |
100g |
RED |
|
|
Dithranol in Lassar's paste 4% w/w |
100g |
RED |
|
|
Dithranol in Lassar's paste 10% w/w |
100g |
RED |
|
|
Dithranol in Lassar's paste 15% w/w |
100g |
RED |
|
|
Dithranol scalp application 0.4% w/w (‘dithranol pomade’; dithranol 0.4% w/w, salicylic acid 2% w/w, emulsifying wax BP 25% w/w, liquid paraffin to 100%) |
100g |
RED |
|
|
KERATOLYTICS |
Salicylic acid 2% w/w and sulfur 2% w/w in aqueous cream |
100g |
AMBER SI |
|
Salicylic acid 5% w/w in emulsifying ointment |
100g |
AMBER SI |
|
|
Salicylic acid 10% w/w in emulsifying ointment |
100g |
AMBER SI |
|
|
Salicylic acid 20% w/w in emulsifying ointment |
100g |
AMBER SI |
|
|
ORAL AND MUCOSAL PREPARATIONS |
Tacrolimus 0.1% w/w in Orabase |
50g |
AMBER SI |
|
Tacrolimus 0.3% w/w in Orabase |
50g |
Non-formulary |
|
|
Triamcinolone acetonide 0.1% w/w in Orabase |
50g |
AMBER SI |
|
|
MISCELLANEOUS |
Diphenylcyclopropenone in acetone 0.00001-6.0% w/v |
10ml |
RED |
|
Glycopyrrolate 2% w/w in cetomacrogol cream |
100g |
AMBER SI |
|
|
Hydroquinone 5% w/w, hydrocortisone 1% w/w and tretinoin 0.1% w/w in a non-aqueous gel |
100g |
AMBER SI |
|
|
Reflectant (Dundee) sunscreens – coffee, coral pink, beige |
50g |
Non-formulary |
|
|
Eosin solution 2% w/v |
100ml |
Non-formulary |
|
|
Sucralfate 4% in emulsifying ointment |
50g |
AMBER SI |
|
|
Sirolimus 0.1% in WSP |
30g |
Non-formulary |
|
|
Sirolimus 0.5% in WSP |
30g |
Non-formulary |
|
|
Phenol 2% w/w in compound zinc paste BP |
50g |
AMBER SI |
|
|
Trichloroacetic acid 90% w/w |
10ml |
Non-formulary |